Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Class of Warrant or Right, Outstanding

Other financials

Income statement

See full
Revenue-—
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0×0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's class of warrant or right, outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's class of warrant or right, outstanding?
Summit Therapeutics (SMMT) reported class of warrant or right, outstanding of $0 in Q1 2026.
How has Summit Therapeutics's class of warrant or right, outstanding changed year-over-year?
Summit Therapeutics's class of warrant or right, outstanding decreased by 100.0% year-over-year, from $1.05M to $0.
What is the long-term trend for Summit Therapeutics's class of warrant or right, outstanding?
Over 2 years (2023 to 2025), Summit Therapeutics's class of warrant or right, outstanding has grown at a -100.0% compound annual growth rate (CAGR), from $5.02M to $0.